New combo therapy hopes to shrink Hard-to-Treat breast tumors
NCT ID NCT07002177
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study tests several new drug combinations containing FWD1802 in people with a common type of advanced breast cancer (ER-positive/HER2-negative) that cannot be removed by surgery or has spread. The study has two parts: first, finding the safest dose (Phase 1), and then checking if the treatment shrinks tumors (Phase 2). About 196 participants will join to see if these combinations are safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center, Shanghai
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.